Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D Mutation

Starting soon · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Pancreatic Cancer, Pancreatic Carcinoma

In brief

This study investigates the first-line treatment of advanced pancreatic cancer with KRAS G12D mutation.The study consists of two stages I, Stage I :explores the combination dose and the second phase; Stage II :patients were randomized 1:1 to receive either the experimental regimen DN022150 plus AG or the control regimen AG alone.

Key facts

Study ID
NCT07656376
Run by
Jiangxi Kvvit Pharmaceutical Co., Ltd.
People needed
465
Starts
2027-06-06
Expected to finish
2029-05-08
Last updated by the study team
2026-06-18

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.